Novo Nordisk has reported 9% net profit increase to Eur 5,1 billion. Diluted earnings per share increased by 11% to Eur 2,01.
The company reported sales of Tresiba Eur 551 million, Victoza Eur 2,7 billion and sales of Saxenda Eur 215 million.
In November 2016, Novo Nordisk received the FDA approval of Xultophy 100/3.6, the once-daily combination of insulin degludec (Tresiba) and liraglutide (Victoza). In January 2017, Novo Nordisk received EU approval of Fiasp, the new-generation fast-acting insulin.
Lars Fruergaard Jørgensen, president and CEO since January 2017 commented on 2016 financial results: “2016 was a challenging year. While we met our financial guidance for the year, strong market headwinds in the USA meant that we had to revise our long-term financial targets. However, 2016 was also a year in which we announced very encouraging clinical data for our key products, providing a solid foundation for future growth.”